Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million on Nov. 26 in a follow-on as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase III REDUCE-IT trial.

The company reiterated plans to submit an sNDA to FDA early next year seeking to expand Vascepa's label to include the cardioprotective effect of the drug observed in the trial. Amarin will also use funds from the offering to expand its sales force...